[A Review of Clinical Studies Investigating Patients with Alzheimer's Disease having Genetic Risk Factors].
Aside from the current conventional pharmaceutical therapies that have limited effects on patients with Alzheimer's disease, disease-modifying therapies have been developed to inhibit the pathological processes of Alzheimer's disease. These include immunotherapies, β/γ secretase inhibitors, and aggregation inhibitors targeting amyloid β. The involvement of genetic risk factors in the effectiveness of such processes has been confirmed. For example, apolipoprotein E ε4 carriers have been reported to have a risk of ARIA (Amyloid Related Imaging Abnormality) as an adverse effect by those therapies. In this paper, we review clinical studies examining patients with Alzheimer's disease, having genetic risk factors.